T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers
Marco Iannetta, Doriana Landi, Gaia Cola, Vincenzo Malagnino, Elisabetta Teti, Daniela Fraboni, Francesco Buccisano, Sandro Grelli, Luigi Coppola, Laura Campogiani, Massimo Andreoni, Girolama Alessandra Marfia, Loredana Sarmati
Topics & Concepts
OcrelizumabMedicineMultiple sclerosisImmunologyAntibodyT cellLymphocyteCD8ELISPOTImmune systemVirologyRituximabSARS-CoV-2 and COVID-19 ResearchMultiple Sclerosis Research StudiesLong-Term Effects of COVID-19